Drug Profile

DA 5219

Alternative Names: DA-5219

Latest Information Update: 12 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Jul 2025 Dong-A ST completes a phase III clinical trials in Gastritis in South Korea (PO) (NCT06151210)
31 Jan 2024 Phase-III clinical trials in Gastritis in South Korea (PO) (NCT06151210)
25 Oct 2023 Dong-A ST receives an IND approval for phase III trial of DA 5219 for the treatment of Gastritis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com